Boris S. Naroditsky

Boris S. Naroditsky

Auto-generated profile, based on publicly available information

Boris S. Naroditsky

The National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Journal of Medical Microbiology
Verified
Journal Article
Closed access
SESvetlana Ermolaeva
Svetlana Ermolaeva
AVAlexander F. Varfolomeev
Alexander F. Varfolomeev
MCMarina Yu. Chernukha
Marina Yu. Chernukha
DYDmitry S. Yurov
Dmitry S. Yurov
MVMikhail M. Vasiliev
Mikhail M. Vasiliev
AGAlexander L. Gintsburg
Alexander L. Gintsburg
Non-thermal (low-temperature) physical plasma is under intensive study as an alternative approach to control superficial wound and skin infections when the effectiveness of chemical agents is weak due to natural pathogen or biofilm resistance. The purpose of this study was to test the individual susceptibility of pathogenic bacteria to non-thermal argon plasma and to measure the effectiveness of plasma treatments against bacteria in biofilms and on wound surfaces. Overall, Gram-negative bacteria were more susceptible to plasma treatment than Gram-positive bacteria. For the Gram-negative bacteriaPseudomonas aeruginosa,Burkholderia cenocepaciaandEscherichia coli, there were no survivors among the initial 105c.f.u. after a 5 min plasma treatment. The susceptibility of Gram-positive bacteria was species- and strain-specific.Streptococcus pyogeneswas the most resistant with 17 % survival of the initial 105c.f.u. after a 5 min plasma treatment.Staphylococcus aureushad a strain-dependent resistance with 0 and 10 % survival from 105c.f.u. of the Sa 78 and ATCC 6538 strains, respectively.Staphylococcus epidermidisandEnterococcus faeciumhad medium resistance. Non-ionized argon gas was not bactericidal. Biofilms partly protected bacteria, with the efficiency of protection dependent on biofilm thickness. Bacteria in deeper biofilm layers survived better after the plasma treatment. A rat model of a superficial slash wound infected withP. aeruginosaand the plasma-sensitiveStaphylococcus aureusstrain Sa 78 was used to assess the efficiency of argon plasma treatment. A 10 min treatment significantly reduced bacterial loads on the wound surface. A 5-day course of daily plasma treatments eliminatedP. aeruginosafrom the plasma-treated animals 2 days earlier than from the control ones. A statistically significant increase in the rate of wound closure was observed in plasma-treated animals after the third day of the course. Wound healing in plasma-treated animals slowed down after the course had been completed. Overall, the results show considerable potential for non-thermal argon plasma in eliminating pathogenic bacteria from biofilms and wound surfaces.

4 April 2011 in Oncotarget
Verified
Journal Article
Open access
PDF file
YBYulia A. Barykova
Yulia A. Barykova
DLDenis Yu. Logunov
Denis Yu. Logunov
MSMaxim Shmarov
Maxim Shmarov
AVAndrei Z. Vinarov
Andrei Z. Vinarov
DFDmitry N. Fiev
Dmitry N. Fiev
MGMarina Antoch and Andrei Gudkov
Marina Antoch and Andrei Gudkov
Association of Mycoplasma hominis infection with prostate cancer

2 February 2017 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
ISInna Shuliakova
Inna Shuliakova
OZO. V. Zubkova
O. V. Zubkova
Amir I. TukhvatulinAmir I. Tukhvatulin
Amir I. Tukhvatulin
ADA. S. Dzharullaeva
A. S. Dzharullaeva
NTN. M. Tukhvatulina
N. M. Tukhvatulina
AGA. L. Gintsburg
A. L. Gintsburg
Ebola hemorrhagic fever, also known as Ebola virus disease or EVD, is one of the most dangerous viral diseases in humans and animals. In this open-label, dose-escalation clinical trial, we assessed the safety, side effects, and immunogenicity of a novel, heterologous prime-boost vaccine against Ebola, which was administered in 2 doses to 84 healthy adults of both sexes between 18 and 55 years. The vaccine consists of live-attenuated recombinant vesicular stomatitis virus (VSV) and adenovirus serotype-5 (Ad5) expressing Ebola envelope glycoprotein. The most common adverse event was pain at the injection site, although no serious adverse events were reported. The vaccine did not significantly impact blood, urine, and immune indices. Seroconversion rate was 100 %. Antigen-specific IgG geometric mean titer at day 42 was 3,277 (95 % confidence interval 2,401–4,473) in volunteers immunized at full dose. Neutralizing antibodies were detected in 93.1 % of volunteers immunized at full dose, with geometric mean titer 20. Antigen-specific response in peripheral blood mononuclear cells was also detected in 100 % of participants, as well as in CD4+ and CD8+ T cells in 82.8 % and 58.6 % of participants vaccinated at full dose, respectively. The data indicate that the vaccine is safe and induces strong humoral and cellular immune response in up to 100 % of healthy adult volunteers, and provide a rationale for testing efficacy in Phase III trials. Indeed, the strong immune response to the vaccine may elicit long-term protection. This trial was registered with grls.rosminzdrav.ru (No. 495*), and with zakupki.gov.ru (No. 0373100043215000055).

29 April 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
LBLyudmila G. Burdelya
Lyudmila G. Burdelya
CBCraig M. Brackett
Craig M. Brackett
BKBojidar Kojouharov
Bojidar Kojouharov
IGIlya I. Gitlin
Ilya I. Gitlin
KLKaterina I. Leonova
Katerina I. Leonova
MGMarina Antoch and Andrei Gudkov
Marina Antoch and Andrei Gudkov
Significance: Toll-like receptor 5 (TLR5) is an innate immunity receptor that specifically recognizes and triggers immune response to bacterial flagellins. In addition to resistance toSalmonellainfection, TLR5 agonists protect mammals from radiation and have anticancer effects, including suppression of tumor metastases. Using mouse models, we defined the liver as a major target for TLR5 agonists. Administration of pharmacologically optimized flagellin derivative CBLB502 leads to rapid activation of prosurvival nuclear factor kappa B (NF-κB) and STAT3 pathways in the liver and rescues mice from lethal doses of hepatotoxic Fas-agonistic antibodies. Thus, TLR5 agonists can be considered for treatment and prevention of liver metastasis and hepatoprotective applications.

14 March 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AKAlexey Kostarnoy
Alexey Kostarnoy
PGPetya G. Gancheva
Petya G. Gancheva
BLBernd Lepenies
Bernd Lepenies
Amir I. TukhvatulinAmir I. Tukhvatulin
Amir I. Tukhvatulin
ADAlina S. Dzharullaeva
Alina S. Dzharullaeva
AGAlexander L. Gintsburg
Alexander L. Gintsburg
Significance: Post-traumatic sterile inflammation is the first necessary step of wound healing. In addition, sterile inflammation underlies the pathogenesis of a multitude of common diseases, such as allergies and autoimmune diseases. The molecular mechanisms underlying sterile inflammation are still not fully understood. Here, we show that the receptor Mincle (Clec4e), the expression of which is highly induced in the skin in response to damage, recognizes cholesterol sulfate, a molecule that is abundant in the epidermal layer of the skin, subsequently inducing a pro-inflammatory response. We also identify a role for Mincle as a driving component in the pathogenesis of allergic skin inflammation. The results demonstrate a previously unconsidered important role of Mincle in mediating sterile inflammation.

7 August 2019 in Toxins
Verified
Journal Article
Open access
PDF file
SGSvetlana Godakova
Svetlana Godakova
ANAnatoly N. Noskov
Anatoly N. Noskov
IVIrina D. Vinogradova
Irina D. Vinogradova
GUGalina A. Ugriumova
Galina A. Ugriumova
ASAndrey Solovyev
Andrey Solovyev
AGAleksandr L. Gintsburg
Aleksandr L. Gintsburg
The bacterium Clostridium botulinum is the causative agent of botulism—a severe intoxication caused by botulinum neurotoxin (BoNT) and characterized by damage to the nervous system. In an effort to develop novel C. botulinum immunotherapeutics, camelid single-domain antibodies (sdAbs, VHHs, or nanobodies) could be used due to their unique structure and characteristics. In this study, VHHs were produced using phage display technology. A total of 15 different monoclonal VHHs were selected based on their comlementarity-determining region 3 (CDR3) sequences. Different toxin lethal dose (LD50) challenges with each selected phage clone were conducted in vivo to check their neutralizing potency. We demonstrated that modification of neutralizing VHHs with a human immunoglobulin G (IgG)1 Fc (fragment crystallizable) fragment (fusionbody, VHH-Fc) significantly increased the circulation time in the blood (up to 14 days). At the same time, VHH-Fc showed the protective activity 1000 times higher than monomeric form when challenged with 5 LD50. Moreover, VHH-Fcs remained protective even 14 days after antibody administration. These results indicate that this VHH-Fc could be used as an effective long term antitoxin protection against botulinum type A.